With 0.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.24 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.5515 whereas the lowest price it dropped to was $4.35. The 52-week range on IVA shows that it touched its highest point at $7.98 and its lowest point at $2.11 during that stretch. It currently has a 1-year price target of $17.07. Beta for the stock currently stands at 0.72.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IVA was up-trending over the past week, with a rise of 8.21%, but this was up by 19.47% over a month. Three-month performance dropped to -22.36% while six-month performance rose 26.55%. The stock gained 109.35% in the past year, while it has gained 69.66% so far this year. A look at the trailing 12-month EPS for IVA yields -4.08 with Next year EPS estimates of -1.20. For the next quarter, that number is -0.34. This implies an EPS growth rate of 55.51% for this year and 19.01% for next year. EPS is expected to grow by 26.61% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -18.31%.
Float and Shares Shorts:
At present, 190.99 million IVA shares are outstanding with a float of 178.16 million shares on hand for trading. On 2025-11-28, short shares totaled 82176.0, which was 4.0 higher than short shares on 1761868800. In addition to Dr. Pierre Broqua Ph.D. as the firm’s Co-Founder, Dr. Martine Zimmermann Pharm.D. serves as its Executive VP of Regulatory Affairs & Quality Assurance.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IVA since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IVA analysts setting a high price target of 26.0 and a low target of 3.0, the average target price over the next 12 months is 15.33333. Based on these targets, IVA could surge 480.36% to reach the target high and fall by -33.04% to reach the target low. Reaching the average price target will result in a growth of 242.26% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.32998 being high and -$1.47359 being low. For IVA, this leads to a yearly average estimate of -$1.40491.
